nantkwest

NEWS

Recent News

NantKwest to Present at the 7th Annual Jefferies Cell Therapy Summit

EL SEGUNDO, Calif. --Sep. 21, 2020-- NantKwest, Inc. (NASDAQ: NK), a clinical-stage, natural killer cell-based therapeutics company, today announced that Patrick Soon-Shiong, M.D., Chairman and CEO, will present at the virtual Jefferies Cell Therapy Summit on Tuesday,...

Hoag Offers Clinical Trial for Pancreatic Cancer Patients

Hoag has been exclusively selected as the only hospital in Orange County, and the only non-academic institution, to offer this promising phase 2 immunotherapy clinical trial for solid tumors. NEWS PROVIDED BY Hoag Memorial Hospital Presbyterian Aug 05, 2020, 14:28 ET...

NantKwest Announces Pricing of Public Offering of Common Stock

EL SEGUNDO, Calif.--Jun. 25, 2020-- NantKwest, Inc. (Nasdaq: NK), a clinical-stage, natural killer cell-based therapeutics company, today announced the pricing of an underwritten public offering of an aggregate of 7,410,000 shares of its common stock (3,700,000 shares...

NantKwest Announces Proposed Public Offering of Common Stock

EL SEGUNDO, Calif.---Jun. 24, 2020-- NantKwest, Inc. (Nasdaq: NK), a clinical-stage, natural killer cell-based therapeutics company, today announced that it intends to offer and sell, subject to market and other conditions, shares of its common stock in an...

Recent News

NantKwest to Present at the 7th Annual Jefferies Cell Therapy Summit

EL SEGUNDO, Calif. --Sep. 21, 2020-- NantKwest, Inc. (NASDAQ: NK), a clinical-stage, natural killer cell-based therapeutics company, today announced that Patrick Soon-Shiong, M.D., Chairman and CEO, will present at the virtual Jefferies Cell Therapy Summit on Tuesday,...

Hoag Offers Clinical Trial for Pancreatic Cancer Patients

Hoag has been exclusively selected as the only hospital in Orange County, and the only non-academic institution, to offer this promising phase 2 immunotherapy clinical trial for solid tumors. NEWS PROVIDED BY Hoag Memorial Hospital Presbyterian Aug 05, 2020, 14:28 ET...

NantKwest Announces Pricing of Public Offering of Common Stock

EL SEGUNDO, Calif.--Jun. 25, 2020-- NantKwest, Inc. (Nasdaq: NK), a clinical-stage, natural killer cell-based therapeutics company, today announced the pricing of an underwritten public offering of an aggregate of 7,410,000 shares of its common stock (3,700,000 shares...

NantKwest Announces Proposed Public Offering of Common Stock

EL SEGUNDO, Calif.---Jun. 24, 2020-- NantKwest, Inc. (Nasdaq: NK), a clinical-stage, natural killer cell-based therapeutics company, today announced that it intends to offer and sell, subject to market and other conditions, shares of its common stock in an...

Current Events

Archives

Media Contact:

Jen Hodson
NantKwest
Telephone: 562-397-3639
Email: Press@NantKwest.com